CODEX Trial: Cognitive outcomes after Dexmedetomidine sedation in cardiac surgery patients
Explore the potential of Dexmedetomidine in preventing Postoperative Cognitive dysfunction (POCD) - A common adverse event after open cardiac surgery.
![Two researchers conduct an experiment](/sites/phcr/files/styles/3_1_1440/public/2024-01/Research%2023%203-01.jpg?itok=cKy1o87V)
About the study
Principal investigator
Dr. Raja Rajamohan
Cardiac Anesthesiologist
Area(s) of medical focus
Brain & Nervous System
Surgical
Mental Health
Condition(s)
Cardiopulmonary disease
Coronary artery disease
Cardiomyopathy
Heart failure
Heart valve disorders
Period of enrollment
2022-05-02 - 2027-05-02
Participating sites
St. Paul's Hospital
Purpose of trial
Compare whether the use of a sedative called Dexmedetomidine after open cardiac surgery reduces the number of patients that develop POCD at 3 month after the surgery.
Dexmedetomidine has been used in the OR for several years already, and some studies have shown that patients who have been sedated with dexmedetomidine have less neurologic complications such as confusion and delirium after the surgery.
It is known that some proportion of the patients having open cardiac surgery may develop a condition similar to delirium called Postoperative Cognitive Dysfunction (POCD) (up to 10-60% at 3 months) and for the moment, there are no proven treatments that can reduce the chances of developing this condition. Since we know that this sedative helps preventing delirium, we believe it will also help preventing long-term cognitive issues such as POCD.
Eligibility
- Age 60 years or older
- Scheduled open cardiac surgery
- Access to computer / email
Poster
Contact information
Additional Information
Study Phase
Phase 4/ Post Market